iShares U.S. Pharmaceuticals ETF (IHE)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in iShares U.S. Pharmaceuticals ETF, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

iShares U.S. Pharmaceuticals ETF (IHE) has returned 2.52% so far this year and 25.22% over the past 12 months. Over the last ten years, IHE has returned 8.08% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since May 5, 2006, IHE's average daily return is +0.05%, while the average monthly return is +0.92%. At this rate, your investment would double in approximately 6.3 years.

Historically, 62% of months were positive and 38% were negative. The best month was Apr 2020 with a return of +13.2%, while the worst month was Oct 2008 at -13.0%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 5 months.

On a daily basis, IHE closed higher 53% of trading days. The best single day was May 7, 2010 with a return of +28.3%, while the worst single day was May 6, 2010 at -26.0%.

iShares U.S. Pharmaceuticals ETF has an annualized alpha of 4.80%, beta of 0.72, and R² of 0.47 versus S&P 500 Index. Calculated based on daily prices since May 08, 2006.

• This ETF participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (88.79%) than losses (79.82%) — typical of diversified or defensive assets.
• R² of 0.47 means the benchmark explains less than half of this ETF's behavior — treat beta with caution or consider switching to a more representative benchmark.

IHE has an expense ratio of 0.42%, placing it in the medium range.

IHE ranks 66 for risk / return — better than 66% of ETFs on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for iShares U.S. Pharmaceuticals ETF (IHE) and compare them to a chosen benchmark (S&P 500 Index).

iShares U.S. Pharmaceuticals ETF provided a 1.72% dividend yield over the last twelve months, with an annual payout of $1.49 per share. The fund has been increasing its distributions for 2 consecutive years.

The table displays the monthly dividend distributions for iShares U.S. Pharmaceuticals ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the iShares U.S. Pharmaceuticals ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the iShares U.S. Pharmaceuticals ETF was 38.20%, occurring on Mar 5, 2009. Recovery took 197 trading sessions.

The current iShares U.S. Pharmaceuticals ETF drawdown is 5.31%.

The chart below shows the rolling one-month volatility.